Comparative cost analysis of cervical cancer screening programme based on molecular detection of HPV in Spain

BMC Women's Health

Table 1 Model inputs

	AHPV versus HC2		AHPV versus Cobas 4800
	AHPV	HC2	AHPV	Cobas
Transition probabilities (%)
Women 35–65 years
HPV positive	7.5% [20]	11.5% [20]	7.5% [20]	12.4% [20]
Abnormal LBC after HPV positive	31.1% [21]	38.5% [23]	31.1% [21]	35.6% [22]
Women 25–34 years
Abnormal LBC	6.5% [21]	6.5% [21]	6.5% [21]	6.5% [21]
ASC-US in patients with abnormal LBC	46.0% [21]	46.0% [21]	46.0% [21]	46.0% [21]
HPV test positive in patients with ASC-US	42.0% [14]	53.0% [14]	53.0% [39]	58.2% [39]
L-SIL + in patients with abnormal LBC	74.1% [40]	74.1% [40]	74.1% [40]	74.1% [40]

ASC-US+: any cytology result from atypical squamous cells of undetermined significance to carcinoma; AHPV: Aptima HPV Assay; HC2: Hybrid Capture 2 Assay; HPV: human papilloma virus; LBC: liquid-base cytology; L-SIL+: any cytology result from low-grade squamous intraepithelial lesions to carcinoma; SD: Standard deviation
^aAverage cost obtained from the list of references identified in the Spanish database
^bIncludes sample-taking costs (human resources, disposables and vial), costs of molecular detection of HPV processing and interpretation of results
^cIncludes costs of molecular detection of HPV processing and interpretation of results; 3. Includes sample-taking costs (human resources, disposables and vial), costs of cytology processing and interpretation
^dIncludes costs of cytology processing and interpretation
^eIncludes the colposcopy procedure with processing and interpretation of one biopsy

ISSN: 1472-6874